Appropriateness of small molecule agents for patients with IBD of childbearing age - a RAND/UCLA appropriateness panel.

ABSTRACT:

Background

Many women of childbearing age with inflammatory bowel disease (IBD) require advanced therapies. While biologics are largely low risk during pregnancy, the novel small molecules tofacitinib, filgotinib, upadacitinib and ozanimod (TFUO) have shown concerning teratogenic effects, and decreased fertility in animal studies. Therefore, their use in women of childbearing age needs careful consideration.

Design

RAND/University of California Los Angeles (UCLA) Appropriateness Method (RAM).

Objective

To evaluate the appropriateness of TFUO in women of childbearing age.

Methods

We convened a panel of six gastroenterologists, two IBD nurses, one IBD pharmacist and three expert patients. Following a literature review, 13 statements were drafted and voted upon in

SUBMITTER: Selinger C 

PROVIDER: S-EPMC11558739 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature